Breast Cancer

David B. Page, MD, medical oncologist, Providence Cancer Center, discusses hormone-directed strategies in the treatment of patients with triple-negative breast cancer (TNBC).

Charlotte Kubicky, MD, PhD, associate professor of radiation medicine, School of Medicine, medical director, Tuality Oregon Health and Science Cancer Center, Oregon Health and Science University, discusses the optimal use of radiation in the treatment of patients with breast cancer.

Haythem Y. Ali, MD, discusses adjuvant advances in HER2-postitive breast cancer and emerging agents in the field.

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses acquired resistance to CDK 4/6 inhibitors in breast cancer.

Lisa A. Newman, MD, director, Breast Oncology Program, Henry Ford Cancer Institute, discusses advances in axillary surgery for the treatment of patients with node-positive breast cancer.

Michael Simon, MD, MPH, medical oncologist, Karmanos Cancer Institute, discusses genomic assays for patients with breast cancer.

Eleanor M. Walker, MD, senior staff physician, division director, Breast Services in the Department of Radiation Oncology, Henry Ford Cancer Institute, discusses the use of radiation therapy in patients with breast cancer.

Dennis J. Slamon, MD, PhD, and Sara A. Hurvitz, MD, discuss the impact of CDK4/6 inhibitors in ER-positive breast cancer.

Rena D. Callahan, MD, discusses controversies in the management of early-stage HR-positive breast cancer and neoadjuvant trial designs for these patients.

Aashini Master, DO, discusses efforts to integrate nutrition and health into breast cancer survivorship.

Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the Mediterranean diet in relation to breast cancer risk.

Maggie DiNome, MD, discusses the evolution of surgical approaches in patients with early-stage breast cancer.

Kelly McCann, MD, PhD, discusses the therapies available for patients with HER2-positive breast cancer and the potential benefit with additional subtyping in the field.

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses the potential benefit of primary tumor surgery for patients with breast cancer.

Susan A. McCloskey, MD, discusses the use of postoperative radiation in patients with breast cancer.

Sara Hurvitz, MD, shares insight on the 3 CDK4/6 inhibitors approved in HR-positive breast cancer, and looks toward the future of these agents, which will likely include combination strategies.

Hatem Soliman, MD, medical oncologist, The Center for Women’s Oncology, Moffitt Cancer Center, discusses the use of combination therapies in the treatment of patients with breast cancer.

Mark Burkard, MD, PhD, discusses an unusual study launched at the University of Wisconsin.